Drug intelligence / Profile preview

avanafil + enalapril

Development stage
Phase 1
Lead developer
VIVUS LLC
Modality
Small Molecules
Administration
Oral
01

Overview

Avanafil + enalapril is a combination of two small molecule pharmaceutical drugs, each with distinct mechanisms and indications. Avanafil is a phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of erectile dysfunction in adult males. It works by selectively inhibiting PDE5, leading to increased levels of cGMP in the corpus cavernosum during sexual stimulation, resulting in smooth muscle relaxation and enhanced blood flow to the penis[3][4][6][8]. Enalapril is an angiotensin-converting enzyme (ACE) inhibitor prodrug indicated for hypertension and congestive heart failure. After hepatic conversion to its active metabolite enalaprilat, it inhibits ACE within the renin–angiotensin–aldosterone system (RAAS), reducing angiotensin II production, causing vasodilation and decreased blood pressure[1][2][5]. There are no known fixed-dose combinations or approved products containing both agents together; this entry describes their pharmacology if co-administered.

Brand names
Spedra
02

Targets

ACE (Angiotensin Converting Enzyme)PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on avanafil + enalapril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on avanafil + enalapril.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call